Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Mirendil, founded by two ex-Anthropic researchers, raised $200M at a $1bn valuation to sell self-improving AI research to everyone.

Don't worry, this post is spoiler-free.

Blake Crouch wrote a popular science-fiction thriller novel that is just screaming for a Hollywood adaptation. So, what's the ...

That brings us to Recursion Pharmaceuticals (RXRX +3.86%), a biotech company specializing in drug discovery using artificial intelligence (AI). At least one notable name in the investing world thinks ...

This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

For over 5 years, Arthur has been professionally covering video games, writing guides and walkthroughs. His passion for video games began at age 10 in 2010 when he first played Gothic, an immersive ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...